Last reviewed · How we verify
PPV Vaccine
PPV vaccine stimulates the immune system to produce antibodies against pneumococcal polysaccharide antigens, providing protection against Streptococcus pneumoniae infection.
PPV vaccine stimulates the immune system to produce antibodies against pneumococcal polysaccharide antigens, providing protection against Streptococcus pneumoniae infection. Used for Prevention of invasive pneumococcal disease (bacteremia, meningitis, pneumonia), Prevention of pneumococcal otitis media and sinusitis.
At a glance
| Generic name | PPV Vaccine |
|---|---|
| Also known as | Pneumovax® |
| Sponsor | Fakultas Kedokteran Universitas Indonesia |
| Drug class | Polysaccharide vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains purified capsular polysaccharides from multiple serotypes of Streptococcus pneumoniae. These polysaccharide antigens trigger B-cell responses and antibody production, conferring humoral immunity against invasive pneumococcal disease. The vaccine is typically administered to high-risk populations including elderly individuals and those with compromised immune systems.
Approved indications
- Prevention of invasive pneumococcal disease caused by Streptococcus pneumoniae
- Prevention of pneumococcal pneumonia in at-risk populations
Common side effects
- Injection site pain or erythema
- Fever
- Myalgia
- Fatigue
Key clinical trials
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting (PHASE3)
- A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis (PHASE3)
- Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine (PHASE4)
- A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine (PHASE4)
- Immune System Function Following Vaccination in HIV Infected Children Taking Anti-HIV Drugs (NA)
- Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults (EARLY_PHASE1)
- Humoral Determinants of Immunity to Pneumococcal Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PPV Vaccine CI brief — competitive landscape report
- PPV Vaccine updates RSS · CI watch RSS
- Fakultas Kedokteran Universitas Indonesia portfolio CI